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Summary
Approximately 3% of the world population is estimated
to have a chronic hepatitis C virus (HCV) infection and
500,000 individuals die from its consequences yearly. Per-
sons who inject drugs (PWID) bear the majority of the dis-
ease burden in high-income countries. Drug substitution
programmes have helped reduce HCV transmissions
among PWID. However, recent epidemics of sexually
transmitted HCV infections in HIV-infected men who have
sex with men demonstrated the changing nature of the
HCV epidemic. HCV therapy is undergoing a revolution,
as new interferon-free, oral treatments eradicate HCV in-
fections in almost all treated patients. As a consequence,
the eradication of HCV has become a matter of debate
and is becoming an important future public health target.
However, for this to be achieved, many challenges need to
be addressed, including the poor uptake of HCV testing, the
high cost of the new antiviral combinations and the high
frequency of re-infections after treatment in some popula-
tions.
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Introduction
The hepatitis C virus (HCV) was discovered in 1989, after
having been first described as “non-A, non-B hepatitis”, a
cause of chronic hepatitis in transfusion recipients in the
1970s [1, 2]. Since then, HCV infection has been increas-
ingly recognised as a major source of liver disease, caus-
ing approximately one quarter of all cases of liver cir-
rhosis and cancer worldwide, and accounting for 500,000
deaths per year [3]. In 2005, over 185 million individuals
(2.8% of the world population) were estimated to be in-
fected with chronic HCV infection, determined as a single
positive anti-HCV antibody test [4]. The highest prevalen-
ce is found in East and Central Asia, as well as in North
Africa, whereas Western Europe is considered to have a
moderate prevalence (1.5%–3.5%). A recent report showed
that, by 2007, HCV infection had even superseded HIV in-
fection as a cause of death in the United States [5].
Approximately 75% of acutely infected patients develop
chronic HCV infection, of whom 20% develop liver cir-
rhosis during the two decades after infection if left un-
treated [6, 7]. The rate of fibrotic progression is influenced
by several risk factors, of which age at infection, sex, hep-
atitis B virus (HBV)-coinfection, alcohol intake, chronic
immune suppression as well as genetic factors are most
important [8]. In a recent genome-wide association study
including data from the Swiss Hepatitis C Cohort Study
(www.swisshcv.ch), several genetic polymorphisms linked
to genes regulating apoptosis were found to be associated
with the development of liver fibrosis [9]. Coinfection with
HIV, which shares routes of transmission with HCV, has a
profound impact on the natural history of HCV-related liv-
er disease: compared with HCV-monoinfected individuals,
coinfected ones are less likely to experience spontaneous
HCV clearance in the early phase of infection, have higher
viral loads and an accelerated progression to liver fibrosis,
cirrhosis, hepatocellular carcinoma and death [10–13].
In industrialised countries, the burden of HCV infection af-
fected mainly persons who inject drugs (PWID) until the
first cases of sexually transmitted infections in HIV-infec-
ted men who have sex with men (MSM) were described
10 years ago (table 1) [14–16]. These reports were fol-
lowed by the description of localised epidemics in large
European cities [17–19] and, finally, nationwide epidemics
among HIV-infected MSM populations, such as the one in
the Swiss HIV Cohort Study [20]. Besides the importance
of specific risk groups, the age of infected individuals, the
viral genotype distribution, as well as the rate of progres-
sion to end-stage liver disease varies widely across settings
[21]. Thus, the epidemiological patterns of HCV infection
must be analysed and interpreted separately for the differ-
ent regions of the world.
For many years, treatment of HCV infection consisted of
weekly injections of pegylated interferon (IFN) alpha and
daily doses of ribavirin (RBV), generally for one year. In
the context of its duration, many contraindications, relat-
ively poor success and high price as well as the many re-
lated side-effects, HCV therapy uptake has been consist-
ently poor [22–24]. However, in the last two years, novel
therapeutic approaches have emerged with the use of direct
acting antivirals (DAA), improving the tolerability and suc-







































cess rate of HCV treatment and creating a new paradigm
in the management of HCV infection [25]. The perspective
to have all-oral, once-daily, pan-genotypic, 2- to 3-month
treatment courses without major side effects or drug inter-
actions and rates of sustained virological responses (SVR)
above 90%, offers hope for the eradication of HCV infec-
tion [26]. However, this goal will only be reached if import-
ant barriers, such as the poor uptake of HCV screening and
the high cost of these new HCV therapies are addressed.
In this review, we summarise the most important aspects
and recent trends in HCV epidemiology, and describe the
impact of new management strategies at the individual and
population level, before discussing the ultimate goal of
HCV eradication and related challenges.
The classic epidemic: HCV infection in
persons who inject drugs
Percutaneous exposure to HCV is the main transmission
route for HCV infection worldwide. Despite well-de-
scribed epidemics in haemophiliacs and dialysis patients in
the 1980s, PWID represent the highest proportion of the
HCV epidemic in Switzerland (table 1). In Europe, the ma-
jority of PWID are infected with HCV: according to a re-
cent systematic review, the global HCV prevalence among
this population group was 67% and over 80% in 12 coun-
tries. Globally, around 10 million active PWID are cur-
rently infected with HCV with more than a million living
each in China, Russia as well as in the USA [27]. Accord-
ing to a recent analysis of data from the national HCV no-
tification system and the Swiss hepatitis C cohort study,
the birth year distribution of HCV infections in Switzer-
land peaks in individuals born between 1955 and 1974,
which correlates with the overall pattern of injection drug
use (IDU) in the Swiss population [28]. Harm-reduction
strategies for PWID such as needle syringe programmes
and opioid substitution treatment have been very successful
for the prevention of HIV infection [29], but have had
more limited impact for HCV prevention, where a combin-
ation of interventions is often needed [30]. Aging cohorts
of HCV-infected patients constitute an increasing pool of
patients at high risk to develop end-stage liver disease and
to die of liver disease.
Eastern Europe and Asia have the largest populations of
PWID infected with HCV [27]. Many countries in these
regions face alarming increases in the incidence of new
HCV infections in these vulnerable populations, partially
because of stigmatising and criminalising laws against
PWID, and due to insufficient resources and the lack of
political will for the implementation of prevention
strategies. Despite the scientific evidence in favour of harm
reduction strategies, punitive instead of therapeutic ap-
proaches for PWID are still frequent in many low- and
middle-income countries and represent a major hurdle in
the fight against the global HCV epidemic.
It has been clearly shown that PWID can be successfully
treated for HCV even in the context of on-going injection
drug use [31]. Nevertheless, HCV treatment uptake in this
population has been consistently low in most settings. As
an example, between 1999 and 2011, the proportion of
HCV-infected PWID from a representative Australian
sample who reported ever having received an HCV therapy
increased slightly, but remained below 10% [32]. The situ-
ation has generally been similar in HIV-infected PWID:
In a single centre of the Swiss HIV Cohort Study, less
than 10% of HIV/HCV-coinfected patients started an HCV
treatment during active follow-up, mainly because of con-
traindications related to other comorbidities and uncon-
trolled addictions [22]. The poor uptake of HCV therapy
in PWID is due to a wide range of barriers, including pa-
tient refusal, comorbidities, continuous injection drug use
and alcohol consumption and the anticipated side-effects of
IFN-based therapy. Furthermore, medical practitioner’s re-
luctance to treat PWID as well as health systems failures
also contribute to the poor access to treatment in many set-
tings. Finally, the suitability of treatment settings and mod-
els of care also seem to play an important role in the ac-
ceptance of HCV treatment for PWID [33].
Table 1: Differences between classic and new HCV epidemics in Switzerland.
Classic epidemic New epidemic
Predominant transmission group PWID (~60%)* MSM (>80%)*
Role of HIV infection Small
(<10% coinfected with HIV)
Important
(>90% coinfected with HIV)
Peak HCV transmissions 1980s 2005 onwards
Estimated number of individuals in
Switzerland*
80,000 200
Estimated treatment uptake** 10% 75%
Re-infection incidence Low (0.8–4.7 per 100 py)*** High (8.0–15.2 per 100 py)****
Preventive measures Needle syringe programmes, opioid substitution
treatment
Condom use, sexual behaviour campaigns
Impact on liver disease burden at the
population level&
Large Small
Transmission rate per infected individual Relatively small in countries with well-established
drug substitution programmes
Relatively large due to continuous risk behaviour
MSM = men who have sex with men; PWID = persons who inject drugs
* from www.swisshcv.ch and Wandeler et al. [20]
** From Wandeler et al. [60] and Dore et al. [21]
*** from Grady et al. [61]
**** from Martin et al. [62] and Lambers et al. [63]
& Number of patients with hepatic decompensation, HCC and liver-related deaths
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The new epidemic: HCV in men who
have sex with men
The possibility of sexual transmission of HCV infection
was raised in several reports in the early 1990’s [34, 35].
In a large sero-survey of over 1,000 patients attending a
genitourinary clinic in London, Tedder and colleagues were
among the first to link the transmission of HCV infection to
MSM sexual practices and the occurrence of other sexually
transmitted infections (STI) [34]. These first epidemiolo-
gical studies were followed by further evidence including
reports from resource-limited countries, which highlighted
the association between HCV and MSM, but the overall
number of infections remained low or the association dis-
appeared after adjusting the estimates for injection drug
use [36, 37]. It was only a few years later that concerns
were raised about the potential increase in the number of
HCV infections in HIV-infected MSM populations who did
not have a history of injection drug use [14–16]. As an
example, in a case note review of a sexual health clinic
in London, the incidence of new HCV seroconversions in
HIV-infected MSM significantly increased between 1997
and 2002, in parallel to the increase in other sexually trans-
mitted infections (STI) such as syphilis [14]. As the num-
ber of incident HCV infections remained low, these ana-
lyses were reproduced in larger cohorts and collaborative
Figure 1
Incident HCV infections by transmission route in the Swiss HIV
Cohort Study.
HET = heterosexual; IDU = injection drug use; MSM = men who
have sex with men (refer to most likely mode of HIV transmission).
Figure 2
Factors associated with the transmission of HCV in HIV-infected
MSM (adapted from Danta et al. [70]).
multi-cohort studies [18, 38]. Small epidemics localised in
large European cities were described in groups of patients
with high risk sexual behaviour, including traumatic anal
intercourse, fisting and the use of sex toys [39]. Several
networks of HCV transmission specific to such high-risk
groups could be shown in England, Germany and the Neth-
erlands, with transmission chains fuelled by permucosal in-
fections [17, 18, 40]. Furthermore, phylogenetic analyses
identified several transmission clusters in Europe and Aus-
tralia within a large international HCV transmission net-
work [41].
In 2012, a comprehensive analysis of HCV seroconver-
sions in the Swiss HIV Cohort Study (SHCS) showed an
18–fold increase in HCV incidence in HIV-infected MSM
between 1998 and 2011, whereas the incidence in PWID
decreased steadily (table 1) [20]. This report was based on
the systematic screening of HCV infection for all SHCS
participants since 1998 and was the first study to report
HCV incidence in a nationwide and representative HIV-in-
fected population. Figure 1 shows the number of incident
HCV infections by calendar year and transmission group in
the SHCS. Incident HCV infections were associated with
unsafe sex and co-infections with syphilis and hepatitis B.
Several biological and behavioural factors seem to play a
role in this new epidemiological trend (fig. 2). More than
separate risk factors, it is probably the interplay between a
number of these that has an impact on the sexual transmis-
sion of HCV in HIV-infected MSM. In addition to the in-
creased biological susceptibility to HCV induced by HIV-
infection and other STI, the consumption of alcohol and
recreational drugs as well as the engagement in unprotected
high risk sexual practices lead to the high vulnerability of
certain HIV-infected MSM. Phylogenetic analyses among
MSM in the SHCS revealed that patients with closely re-
lated HIV viruses were more likely to acquire HCV in-
fection if their partner was HCV-positive [42]. This find-
ing underscores the role of domestic HCV transmission
linked to sexual risk behaviour. Seroadaptive behaviour
(‘serosorting’) is increasingly common in HIV-infected
MSM, leading to the broader uptake of unprotected, trau-
matic sexual practices [43]. Importantly, Hasse et al.
showed that, in Switzerland, condom use had decreased
among HIV-infected individuals with an undetectable HIV
viral load during anti-retroviral therapy in recent years, fur-
ther increasing the proportion of individuals at risk of HCV
infection [44]. Kouyos and colleagues found a broad HIV
transmission bottleneck in HCV-infected MSM [45]. As a
broad bottleneck is consistent with direct viral transmission
through traumatic events, this finding supports the role of
traumatic sex for HCV transmission among HIV-infected
MSM (fig. 2).
Is the HCV epidemic only changing in
HIV-infected individuals?
According to the Global Burden of Diseases Project (GBD
2010), the prevalence of people with anti-HCV has in-
creased from 2.3% to 2.8% between 1990 and 2005 glob-
ally [4]. Even though trends in HCV incidence vary across
countries, the main drivers of HCV infection in the general
population have remained fairly stable over the past years
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[46]. Injection drug use remains the main mode of trans-
mission in industrialised countries, whereas unsterile tat-
toos and piercings in non-professional settings might play
an increasing role in young populations [47]. Risk factors
for HCV infection in resource-limited settings remain ill-
defined, even though unsafe therapeutic injection practices
and blood transfusions seem to be the main routes of infec-
tion [46].
In Switzerland, there were an estimated 82,000 viraemic
HCV infections in 2013 [48]. According to this study, the
viraemic population peaked in 1996 and was projected to
decrease to 63,000 by 2013 due to intensified treatment
and reduced transmissions. However, the proportion of ad-
vanced liver fibrosis or hepatic decompensations was pro-
jected to increase and account for more than 20% of total
infections by 2030. This indicates that the disease burden
caused by HCV infections will continue to rise in the next
decades if treatment uptake and efficacy do not increase
substantially. Bruggmann and colleagues estimated that, if
treatment uptake increases from currently 1,100 to 5,300
per year, test rate increased from 1,050 to 3,490 per year,
and if treatment efficacy rises to 90% using the new DAA
regimens, HCV-related mortality would decline by 70%
and 1,640 liver-related deaths would be averted by 2030
in Switzerland. This indicates that treatment interventions
could indeed have a substantial impact on the morbidity
and mortality at the population level.
The landscape of HCV epidemiology in HIV-infected pa-
tients has changed in recent years due to the increasing
role played by its sexual transmission in MSM and the de-
creasing incidence in injection drug use in PWID. In the
context of successful harm reduction strategies for PWID
in Switzerland, the number of HCV-infected patients en-
tering HIV care has decreased in recent years, whereas
the number of incident HCV infections during follow-up
has increased. The new epidemic of HCV infections in
HIV-infected MSM and the potentially increased sexual
transmission of HCV reported in cohorts of HIV-infected
women [49] raised the question of whether sexual trans-
missions of HCV could also occur in HIV-uninfected indi-
viduals.
Among HIV-uninfected heterosexual people in long-term
monogamous relationships, the risk of sexual transmission
of HCV is extremely low. Most spousal transmissions seem
to be explained by the common practice of sharing syringes
[50]. However, the probability of acquiring HCV infection
has been shown to increase with the number of sexual part-
ners [51]. A recent systematic review on the sexual trans-
mission of HCV underlined the importance of confounding
by other risk factors in the majority of these epidemiolo-
gical studies [52]. Most reports showing an association
between heterosexual contact and the acquisition of HCV
infection relied on self-reports as ascertainment of injection
drug use and exposure to other sources of infection includ-
ing sharp objects could not be excluded. HIV-uninfected
MSM do not seem to be at higher risk of acquiring HCV
either. In a recent serological survey among over 800 HIV-
uninfected MSM with a median of 6 sexual partners a year
in Zurich, the prevalence of anti-HCV was 0.4% and only
one patient had a replicating HCV infection [53]. Thus,
HCV prevalence in HIV-uninfected MSM in Switzerland
does not seem to be higher than in the general popula-
tion despite the large proportion of these men reporting un-
protected anal intercourse and traumatic sexual practices.
These results are comparable to most other evaluations in
European, Australian and American cities and are in line
with a recent systematic review which came to the conclu-
sion that systematic screening of HCV infection in HIV-un-
infected MSM was not recommended [54]. Taken together,
the literature available to date does not place sexual trans-
mission as an important mode of transmission of HCV in
HIV-uninfected individuals.
HCV eradication: a realistic goal?
The field of HCV infection is facing an unprecedented situ-
ation in terms of treatment perspectives. The better under-
standing of the HCV life cycle as well as important efforts
in drug development, have led to the discovery of sever-
al direct-acting antiviral agents (DAA) [25]. Within a few
years, we have moved from lengthy courses of IFN-based
treatment with many side-effects and poor treatment suc-
cess to shorter treatments with well-tolerated and more po-
tent oral drugs. Within the next two years, most HCV-infec-
ted patients, including those with cirrhosis, HIV-infection
and those who failed previous therapies, will benefit from
atwo to three-month course of all-oral treatment regimens
with over 90% chances of experiencing a sustained virolo-
gical response. As successful antiviral therapy is associated
with a decreased progression to end-stage liver disease and
mortality, as well as with an improved quality of life, it is
now clear that much of the HCV-related morbidity can be
controlled with treatment [55]. The new treatment options
have moved the discussion from individual treatment effic-
acy to the ambitious goal of global elimination (reduction
of incidence to zero but requiring preventive measures to
prevent re-establishment, as with measles) or even eradica-
tion (permanent reduction to zero cases, as with smallpox)
[56].
The control of HCV infection implies primary prevention
measures, such as the testing of blood supplies and ensur-
ing safe injections and medical procedures, combined with
the management of existing infections. As the pool of ex-
Figure 3
HCV prevalence, diagnosis and treatment rates in 2013 (from: Dore
GJ, Ward J, Thursz M. Hepatitis C disease burden and strategies to
manage the burden. J Viral Hepat. 2014;21(Suppl 1):1–4, reprint
with permission from John Wiley and Sons).
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isting infections is extremely large, increasing the uptake
of HCV testing and treatment is a necessity and remains
the main challenge on the road to HCV eradication. Lack
of HCV awareness and access to health care for those at
highest risk are the main barriers to overcome. At present,
there are wide differences in testing and treatment uptake
between countries, as shown in figure 3 for Europe. In the
United States, more than half of HCV-infected individuals
are unaware of their infection [57], and this proportion is
even much higher in resource-limited settings. Sound HCV
testing strategies focused on specific age groups and high-
risk populations have been implemented in several coun-
tries. These strategies need to be adapted to the local epi-
demiologic situation, and to go along with interventions to
improve access to care and treatment for those in need. The
slowly increasing availability of point-of-care anti-HCV
tests should also have an impact on the uptake of HCV
screening, especially in low-income settings.
In all regions of the world, only a small minority of HCV-
infected patients have ever received IFN-alpha-based an-
tiviral therapy. In low and middle income countries, HCV
treatment is not accessible for almost all affected persons
and treatment uptake rates remain below 1%. By the end
of 2005, treatment uptake in European countries was estim-
ated to range between 16% in France and 1% in Romania
and Russia [58]. These numbers have not increased after
the availability of the first generation of DAA including
boceprevir and telaprevir. Only 12% of the patients with a
chronic HCV infection in 2011 in the Swiss HIV Cohort
Study started HCV therapy with one of the new protease
inhibitors during follow-up [59]. However, recent trends in
HCV epidemiology already had an impact on treatment up-
take during acute HCV infection, as shown in a recent ana-
lysis in HIV-infected patients in Switzerland [60]. Treat-
ment uptake in incident HCV infections has increased from
33% before 2005 to 75% after 2005. These results were
mainly driven by the large proportion of MSM accounting
for incident HCV infections in the SHCS after this date.
However, similar trends can be expected for PWID in the
future, as it is increasingly recognised that the willingness
for treatment is high and that it is effective and cost-effi-
cient in this population [56].
Another challenge for HCV eradication is the high fre-
quency of HCV re-infections in certain patient populations.
Whereas this does not seem to be a major issue in PWID,
where re-infections are rare even in the context of on-going
injection drug use [61], early reports from HIV-infected
MSM cohorts are of greater concern. Among 145 HIV-in-
fected MSM with a documented primary HCV infection at
a large hospital in London, the re-infection rate was 8.0 per
100 person-years over a median follow-up time of 2.1 years
[62]. In another study from Amsterdam, the incidence of
re-infection was even higher, with an estimated 15.2 per
100 person-years [63]. These results underline the need for
more extensive risk behaviour counselling and prevention
in certain high-risk groups such as HIV-infected MSM in
large European cities.
The soon-to-be available interferon-free, pangenotypic,
single-tablet antiviral combinations for HCV infection will
undoubtedly increase the overall treatment uptake provided
its accessibility is improved through cost-reductions. One
of the greatest assets of these newer generations of antiviral
treatment is their broad applicability in general clinical
practices or in resource-limited settings due to their safety
and relative simplicity in management and monitoring [64].
In analogy to the long-lasting fight for affordable anti-ret-
roviral therapy for HIV infection in Africa, similar efforts
will have to be made for HCV therapies in order to expect
an impact of these new treatment modalities on the glob-
al HCV epidemic [65]. In Switzerland, the high cost of the
new HCV drugs has limited their promising potential in
terms of treatment uptake as their prescription is currently
restricted to patients with advanced liver disease.
The new therapeutic strategies have also led experts to
advocate HCV treatment as prevention, in analogy to re-
cent developments in the field of HIV infection [66]. In
contrast to HIV infection, HCV treatment is finite in time
and often leads to cure. Thus, it is obvious that a com-
bination of enhanced HCV treatment efficacy as well as
improved diagnosis and treatment uptake would have a
huge impact on population-level disease burden. Further-
more, treatment as prevention strategies could also be a
way to address re-infections in high-risk groups. Mathem-
atical modelling work has given important insights into the
feasibility of treatment as prevention. The introduction of
new DAAs will only have a modest impact on projected
advanced liver disease burden, mortality and the number
of new infections if treatment uptake remains at current
levels [21, 67]. However, according to a recently published
modelling study adapted for PWID populations in Scot-
land, Canada and Australia, realistic increases in treatment
uptake of DAA-based antiviral therapies could halve the
HCV prevalence within the next 15 years [68]. Finally, in a
similar model adapted to the HCV epidemic in HIV-infec-
ted MSM in Switzerland, condom use and HCV treatment
uptake were the most important factors in curbing the epi-
demic in this population [A. Rauch, SSI Annual Meeting
Aarau, August 2014].
Conclusions
The HCV epidemic has evolved over the years: besides the
constant burden seen in PWID, smaller epidemics of sexu-
ally transmitted HCV infections have recently emerged in
HIV-infected MSM. After two decades of slow and incre-
mental improvements in HCV therapy, a new era has star-
ted with the availability of new generations of oral, direct-
acting antiviral drugs, allowing new perspectives in terms
of HCV control. HCV infection has many of the attributes
needed to be a good candidate for eradication: it can be
cleared from the host through treatment, there is no non-
human reservoir and transmission chains can be broken.
However, the poor uptake of HCV testing, the high cost of
the new antiviral therapies as well as the frequent re-infec-
tions after successful treatments are some of the challenges
that will need to be addressed for the better control of the
HCV epidemic. Furthermore, the eradication of an infec-
tious agent needs strong financial support as well as politic-
al and societal will. Although these factors have not always
been present in the past years, the call to develop a com-
prehensive approach to control chronic hepatitis during the
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2010 World Health Assembly [69] leaves hope for a better
control of HCV worldwide.
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Figures (large format)
Figure 1
Incident HCV infections by transmission route in the Swiss HIV Cohort Study.
HET = heterosexual; IDU = injection drug use; MSM = men who have sex with men (refer to most likely mode of HIV transmission).
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Figure 2
Factors associated with the transmission of HCV in HIV-infected MSM (adapted from Danta et al. [70]).
Figure 3
HCV prevalence, diagnosis and treatment rates in 2013 (from Dore et al. [21]).
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